ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
港股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
科伦博泰生物-B
435.000
-30.000
-6.45%
手动刷新
成交量:
83.37万
成交额:
3.67亿
市值:
1,014.36亿
市盈率:
-330.46
高:
475.000
开:
475.000
低:
428.800
收:
465.000
52周最高:
581.000
52周最低:
152.000
股本:
2.33亿
香港流通股本:
1.63亿
量比:
1.25
换手率:
0.51%
股息:
- -
股息率:
- -
每股收益(LYR):
-1.316
净资产收益率:
-17.56%
总资产收益率:
-9.92%
市净率:
18.50
市盈率(LYR):
-330.46
市销率:
61.80
数据加载中...
总览
公司
新闻资讯
公告
三阴性乳腺癌变局来袭
新浪医药
·
10/30
每日卖空追踪 | 科伦博泰生物-B 10月30日卖空量成交4万股,卖空比例为2.87%
市场透视
·
10/30
科伦博泰生物-B盘中异动 快速下挫5.07%报400.400港元
市场透视
·
10/30
港生物医药股集体下挫!药明康德跌近6%,荣昌生物跌超4%
老虎资讯综合
·
10/30
中国医药:关注已授权药物的研发推进
招银国际
·
10/27
国产RET抗癌药三强陆续申请上市,进口药年治疗费用超40万元
红星新闻
·
10/24
每日卖空追踪 | 科伦博泰生物-B 10月24日卖空量成交1.46万股,卖空比例为1.99%
市场透视
·
10/24
科伦博泰生物-B盘中异动 下午盘股价大涨3.00%报439.800港元
市场透视
·
10/24
港股异动 | 生物技术股走弱,荣昌生物跌近12%
老虎资讯综合
·
10/23
生物制药行业ESMO大会数据研究:聚焦ESMO大会:重磅汇报密集,国产新药成为全场焦点
国金证券
·
10/23
科伦博泰生物-B盘中异动 股价大跌3.31%
市场透视
·
10/23
【券商聚焦】天风证券维持科伦博泰生物-B(06990)“买入”评级 指公司核心产品商业化进程顺利
金吾财讯
·
10/23
每日卖空追踪 | 科伦博泰生物-B 10月22日卖空量成交3.23万股,卖空比例为4.58%
市场透视
·
10/22
三季报密集披露 绩优基金调仓曝光!任桀:全球云计算产业仍然值得重点关注
东方财富
·
10/22
交银国际:维持科伦博泰生物-B(06990)“买入”评级 目标价上升至549港元
智通财经
·
10/22
科伦博泰生物-B盘中异动 大幅上涨3.61%
市场透视
·
10/22
ESMO炸场!中国ADC“一哥”亮剑
智通财经
·
10/20
医药行业再传捷报!科伦博泰重磅乳腺癌创新药获批上市
制药网
·
10/20
科伦博泰生物-B在ESMO总统会议上展示的Sacituzumab Tirumotecan三期Optitrop-Lung04试验积极结果同时发表在NEJM
美股速递
·
10/20
港股异动 | 科伦博泰生物-B(06990)高开逾5% 于2025 ESMO大会上公布佳泰莱®等多项临床研究成果
智通财经
·
10/20
更多
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/06990/news?page=2"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":435,"timestamp":1763366895008,"preClose":465,"halted":0,"volume":833749,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.316358152154308,"marketStatus":"未开盘","change":-30,"latestTime":"11-17 16:08:15","open":475,"high":475,"low":428.8,"amount":367302701,"amplitude":0.099355,"askPrice":435,"askSize":4800,"bidPrice":434.8,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.502237887596598,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":465,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"volumeRatio":1.2528324942538682,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":162769979,"roa":"-9.92%","roe":"-17.56%","lyrEps":-1.316358,"volumeRatio":1.2528324942538682,"shares":233185969,"dividePrice":0,"high":475,"amplitude":0.099355,"preClose":465,"low":428.8,"week52Low":152,"pbRate":"18.50","psRate":"61.80","week52High":581,"institutionHeld":0,"latestPrice":435,"committee":-0.959184,"eps":-1.316358152154308,"divideRate":0,"volume":833749,"delay":0,"ttmEps":-3.502237887596598,"open":475,"prevYearClose":163.3,"prevWeekClose":465,"prevMonthClose":448,"prevQuarterClose":514,"fiveDayClose":413.4,"twentyDayClose":458.4,"sixtyDayClose":431},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-08-18","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盘后","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盘后","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":18,"updateTime":1755964800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-11-14","current":-124.216367,"percent":0.478485,"low":-351.800852,"twenty":-201.138492,"median":-131.729362,"eighty":-48.622244,"high":-21.029201,"avg":-126.801387,"sd":82.155159,"marketCap":108431475585},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200},{"date":"2025-04-25","current":-235.137362,"twenty":-160.624501,"median":-68.953584,"eighty":-45.131919,"marketCap":66771338400},{"date":"2025-05-02","current":-274.570331,"twenty":-161.195254,"median":-69.468586,"eighty":-45.197413,"marketCap":78134738400},{"date":"2025-05-09","current":-249.374354,"twenty":-161.514906,"median":-70.050704,"eighty":-45.202208,"marketCap":71462875059},{"date":"2025-05-16","current":-247.507619,"twenty":-162.87029,"median":-70.732965,"eighty":-45.217068,"marketCap":71507400214},{"date":"2025-05-23","current":-244.618313,"twenty":-163.824551,"median":-71.32983,"eighty":-45.58151,"marketCap":70884048033},{"date":"2025-05-30","current":-244.159494,"twenty":-165.025774,"median":-71.669987,"eighty":-45.601984,"marketCap":71062148656},{"date":"2025-06-06","current":-258.187076,"twenty":-166.004403,"median":-72.203519,"eighty":-46.006494,"marketCap":75336563613},{"date":"2025-06-13","current":-271.678883,"twenty":-167.701589,"median":-72.488214,"eighty":-46.133909,"marketCap":79304691313},{"date":"2025-06-20","current":-252.757485,"twenty":-168.349452,"median":-72.789206,"eighty":-46.315126,"marketCap":73636805593},{"date":"2025-06-27","current":-255.806605,"twenty":-169.647858,"median":-73.569836,"eighty":-46.457129,"marketCap":74733815733},{"date":"2025-07-04","current":-283.173205,"twenty":-171.495185,"median":-73.869687,"eighty":-46.685504,"marketCap":82732847998},{"date":"2025-07-11","current":-266.231967,"twenty":-173.142078,"median":-74.539848,"eighty":-46.749361,"marketCap":77704884860},{"date":"2025-07-18","current":-304.526119,"twenty":-187.755426,"median":-75.01675,"eighty":-46.798833,"marketCap":88812112519},{"date":"2025-07-25","current":-289.211949,"twenty":-196.095673,"median":-75.38559,"eighty":-46.877904,"marketCap":84652615741},{"date":"2025-08-01","current":-318.351212,"twenty":-209.071662,"median":-75.715906,"eighty":-46.908544,"marketCap":92605939250},{"date":"2025-08-08","current":-315.832709,"twenty":-214.487876,"median":-76.34536,"eighty":-47.149906,"marketCap":92103142937},{"date":"2025-08-15","current":-340.637946,"twenty":-221.73884,"median":-77.157567,"eighty":-47.354138,"marketCap":99188000086},{"date":"2025-08-22","current":-135.707825,"twenty":-221.73884,"median":-78.335478,"eighty":-47.421279,"marketCap":106638527281},{"date":"2025-08-29","current":-131.473703,"twenty":-217.466422,"median":-78.819337,"eighty":-47.438439,"marketCap":103804584421},{"date":"2025-09-05","current":-151.82862,"twenty":-215.82299,"median":-80.340969,"eighty":-47.449348,"marketCap":119756940196},{"date":"2025-09-12","current":-146.494298,"twenty":-214.791029,"median":-81.555855,"eighty":-47.474394,"marketCap":115757424063},{"date":"2025-09-19","current":-147.466634,"twenty":-214.487876,"median":-85.53437,"eighty":-47.73502,"marketCap":116443055400},{"date":"2025-09-26","current":-143.954691,"twenty":-214.295448,"median":-89.950081,"eighty":-47.938811,"marketCap":113375018127},{"date":"2025-10-03","current":-165.853778,"twenty":-213.463042,"median":-128.34687,"eighty":-48.070155,"marketCap":130933921593},{"date":"2025-10-10","current":-144.531455,"twenty":-212.219938,"median":-131.729362,"eighty":-48.217901,"marketCap":113934664453},{"date":"2025-10-17","current":-135.703716,"twenty":-210.108236,"median":-132.867642,"eighty":-48.374971,"marketCap":106892448189},{"date":"2025-10-24","current":-129.499037,"twenty":-207.014216,"median":-133.546653,"eighty":-48.434282,"marketCap":102042180034},{"date":"2025-10-31","current":-132.379263,"twenty":-204.550971,"median":-132.326202,"eighty":-48.483234,"marketCap":104467314112},{"date":"2025-11-07","current":-120.930715,"twenty":-203.710245,"median":-131.985022,"eighty":-48.610423,"marketCap":95373061321},{"date":"2025-11-14","current":-137.099974,"twenty":-201.138492,"median":-131.729362,"eighty":-48.622244,"marketCap":108431475585}],"updateTime":1763375360958},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579262241","title":"三阴性乳腺癌变局来袭","url":"https://stock-news.laohu8.com/highlight/detail?id=2579262241","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579262241?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 19:28","pubTimestamp":1761823723,"startTime":"0","endTime":"0","summary":"撰文丨大眼怪三阴性乳腺癌因其侵袭性强、治疗选择有限且预后差,一直是乳腺癌治疗领域的巨大挑战。目前获批用于三阴性乳腺癌后线治疗的TROP2 ADC药物主要有两款,分别是戈沙妥珠单抗与芦康沙妥珠单抗。其中,全球首个TROP2 ADC戈沙妥珠单抗已在多国获批适应症,用于既往接受过至少2种全身治疗的转移性三阴性乳腺癌,并且获得国内外众多指南一致推荐,成为TNBC二线及以后治疗的标准方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030213210a47dfca6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030213210a47dfca6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","01877","BK1583","09966","BK1515"],"gpt_icon":0},{"id":"2579486952","title":"每日卖空追踪 | 科伦博泰生物-B 10月30日卖空量成交4万股,卖空比例为2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579486952","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579486952?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 16:30","pubTimestamp":1761813034,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间10月30日,跌0.05%,卖空量成交4万股,较上一交易日增加16.28%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030163655a47d676f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030163655a47d676f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2579648699","title":"科伦博泰生物-B盘中异动 快速下挫5.07%报400.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579648699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579648699?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 09:48","pubTimestamp":1761788892,"startTime":"0","endTime":"0","summary":"2025年10月30日早盘09时48分,科伦博泰生物-B股票出现异动,股价急速跳水5.07%。截至发稿,该股报400.400港元/股,成交量11.95万股,换手率0.07%,振幅3.94%。资金方面,该股资金流入1559.07万港元,流出2335.95万港元。科伦博泰生物-B股票所在的生物技术行业中,整体跌幅为1.46%。科伦博泰生物-B公司简介:四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030094812a47cb8c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251030094812a47cb8c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"1103851479","title":"港生物医药股集体下挫!药明康德跌近6%,荣昌生物跌超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103851479","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103851479?lang=zh_cn&edition=fundamental","pubTime":"2025-10-30 09:47","pubTimestamp":1761788840,"startTime":"0","endTime":"0","summary":"10月30日,港股$生物(000504)$医药股集体下挫,$药明康德(02359)$跌近6%,$科伦博泰生物-B(06990)$、$荣昌生物(09995)$跌超4%,$药明生物(02269)$、$君实生物(688180)$跌超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c7160e78ba353b4ae3f9f3905da7b30f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02359","02269","06990","09939"],"gpt_icon":0},{"id":"2578892667","title":"中国医药:关注已授权药物的研发推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2578892667","media":"招银国际","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578892667?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 00:00","pubTimestamp":1761494400,"startTime":"0","endTime":"0","summary":"由于资本市场融资复苏、创新药出海交易规模上涨,国内创新药研发需求出现回暖。此外,建议投资人关注已授权的创新药管线在海外的临床推进。关于IBI363,信达生物将承担40%的全球研发费用,并分享40%的美国商业权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510270936359743c0a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510270936359743c0a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU2097828631.EUR","LU2242644610.SGD","BK1589","01801","LU2097828714.EUR","BK1161","LU0455707207.USD","LU2328871848.SGD","LU0502904849.HKD","LU1969619763.USD","LU2097828557.USD","LU2097828474.EUR","LU2488822045.USD","LU2097828805.USD","BK1583"],"gpt_icon":1},{"id":"2577543613","title":"国产RET抗癌药三强陆续申请上市,进口药年治疗费用超40万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577543613","media":"红星新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577543613?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 23:16","pubTimestamp":1761318960,"startTime":"0","endTime":"0","summary":"红星资本局注意到,今年已有三款国产RET抗癌药先后获批。资料图三款国产RET抗癌药获批上市RET基因融合是恶性肿瘤的重要驱动因素,临床常见于非小细胞肺癌。自此,国产RET抗癌药“三强”均已进入最后冲线阶段。目前在售RET抗癌药均为进口药年治疗费用超40万元截至目前,国内在售的RET抗癌药仅有两款,分别是Blueprint Medicines的普拉替尼、礼来的塞普替尼,两者均为进口药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102423172294dbd82a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102423172294dbd82a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","01801","LU2097828474.EUR","BK1589","02616","LU1969619763.USD","LU2488822045.USD","LU2097828557.USD","BK1161","06990","LU0502904849.HKD","LU2242644610.SGD","LU2097828631.EUR","BK1191","LU2097828714.EUR","LU2328871848.SGD","LU0455707207.USD","BK1574","BK1583","LU2097828805.USD","LU0196878994.USD"],"gpt_icon":0},{"id":"2578192528","title":"每日卖空追踪 | 科伦博泰生物-B 10月24日卖空量成交1.46万股,卖空比例为1.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578192528","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578192528?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 16:30","pubTimestamp":1761294636,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间10月24日,涨2.48%,卖空量成交1.46万股,较上一交易日减少63.77%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024163615a4724a01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251024163615a4724a01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2578528133","title":"科伦博泰生物-B盘中异动 下午盘股价大涨3.00%报439.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578528133","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578528133?lang=zh_cn&edition=fundamental","pubTime":"2025-10-24 14:49","pubTimestamp":1761288561,"startTime":"0","endTime":"0","summary":"2025年10月24日下午盘14时49分,科伦博泰生物-B股票出现波动,股价快速上涨3.00%。科伦博泰生物-B股票所在的生物技术行业中,整体涨幅为1.51%。消息层面,截至14时49分,《交银国际:维持科伦博泰生物-B“买入”评级 目标价上升至549港元》资讯为影响科伦博泰生物-B的重要信息。该行的DCF目标价上升至549港元,维持科伦博泰生物-B“买入”评级,看好临床数据驱动下ADC产品矩阵的巨大全球价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102414492194db0f04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102414492194db0f04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"1152404472","title":"港股异动 | 生物技术股走弱,荣昌生物跌近12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152404472","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152404472?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 13:25","pubTimestamp":1761197137,"startTime":"0","endTime":"0","summary":"10月23日,港股$生物(000504)$技术股盘中走弱,$荣昌生物(09995)$跌近12%,$药捷安康-B(02617)$跌超8%,$科伦博泰生物-B(06990)$跌超6%,$晶泰控股(02228)$、$映恩生物-B(09606)$跌近6%,$药明生物(02269)$、$康方生物(09926)$、$百济神州(06160)$跟跌。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df43def6c60d84e15ce9d1605944911d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","06990","02269","02228","02617","09995","ONC","09606","06160"],"gpt_icon":0},{"id":"2577328718","title":"生物制药行业ESMO大会数据研究:聚焦ESMO大会:重磅汇报密集,国产新药成为全场焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2577328718","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577328718?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 10:07","pubTimestamp":1761185250,"startTime":"0","endTime":"0","summary":"中国药企重磅研究发布数量刷新历史记录,成为ESMO会议的全场焦点。2025年ESMO年会于欧洲当地时间10月17日至21日在德国柏林以线上+线下的形式举行,多项创新药研究在ESMO披露重磅数据,创新药行业迎来每年的重要投资窗口之一。投资建议与估值随着多款中国创新药数据在ESMO密集发布,且PD-1PLUS双抗、ADC等领域的临床数据达到国际领先水平,引起较高关注,或有望提振创新药新一轮的出海机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023100743973d9752&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251023100743973d9752&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","BK1191","LU1023057109.AUD","01276","LU2543165471.USD","09926","06990","LU0359202008.SGD","09995","LU0359201612.USD"],"gpt_icon":0},{"id":"2577332552","title":"科伦博泰生物-B盘中异动 股价大跌3.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577332552","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577332552?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 09:39","pubTimestamp":1761183598,"startTime":"0","endTime":"0","summary":"2025年10月23日早盘09时39分,科伦博泰生物-B股票出现异动,股价大幅下挫3.31%。科伦博泰生物-B股票所在的生物技术行业中,整体涨幅为0.37%。其相关个股中,药捷安康-B、永泰生物-B、复宏汉霖涨幅较大,振幅较大的相关个股有轩竹生物-B、药捷安康-B、三叶草生物-B,振幅分别为11.00%、10.36%、5.31%。该行的DCF目标价上升至549港元,维持科伦博泰生物-B“买入”评级,看好临床数据驱动下ADC产品矩阵的巨大全球价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102309395894d8b205&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102309395894d8b205&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2577344956","title":"【券商聚焦】天风证券维持科伦博泰生物-B(06990)“买入”评级 指公司核心产品商业化进程顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2577344956","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577344956?lang=zh_cn&edition=fundamental","pubTime":"2025-10-23 09:19","pubTimestamp":1761182388,"startTime":"0","endTime":"0","summary":"金吾财讯 | 天风证券研报指出,近日,科伦博泰生物-B 核心产品sac-TMT在2025ESMO上公布了关于乳腺癌、非小细胞肺癌的两项重磅III期研究的积极结果,分别是HR+/HER2-BC2L适应症的OptiTROP-Breast02研究和EGFRTKI耐药后EGFR突变NSCLC患者的III期OptiTROP-Lung04研究。该机构表示,考虑到公司核心产品商业化进程顺利,该机构预计公司2025-2027年营业收入分别为20.84亿元、28.76亿元和46.63亿元;归母净利润分别为-6.22亿元、-1.30亿元和5.61亿元。维持“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1968329","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601162","06990"],"gpt_icon":0},{"id":"2577657463","title":"每日卖空追踪 | 科伦博泰生物-B 10月22日卖空量成交3.23万股,卖空比例为4.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577657463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577657463?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 16:30","pubTimestamp":1761121836,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间10月22日,跌3.74%,卖空量成交3.23万股,较上一交易日减少76.75%更多个股卖空数据请看下面视窗:卖空数据是观测市场多空博弈的关键指标:短期可反映市场情绪,高卖空比例预示看空预期,但极端值可能触发轧空反弹;长期结合基本面恶化则预警下行风险。需注意其局限性:卖空行为包含对冲需求,未必单纯看空;机构可能通过衍生品做空未体现在数据中,且散户跟风易扭曲信号。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022163526a6c7948b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022163526a6c7948b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2577363429","title":"三季报密集披露 绩优基金调仓曝光!任桀:全球云计算产业仍然值得重点关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2577363429","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577363429?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 15:49","pubTimestamp":1761119351,"startTime":"0","endTime":"0","summary":"三季报密集披露,绩优基金调仓曝光公募三季报密集披露,绩优基金经理持仓动向备受市场关注。10月22日,前三季度“冠军基”、年内暴赚近195%的永赢科技智选,“翻倍基”长城医药产业精选等披露三季报,这些绩优基金大多重仓云计算、创新药等热门方向。截至三季度末,该基金保持高仓位运作,股票仓位超91%。在三季报中,任桀表示,全球云计算产业仍值得重点关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022154928a46dfbd2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022154928a46dfbd2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","01530","06990","BK1161","BK1593"],"gpt_icon":0},{"id":"2577308213","title":"交银国际:维持科伦博泰生物-B(06990)“买入”评级 目标价上升至549港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2577308213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577308213?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 14:31","pubTimestamp":1761114699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,交银国际发布研报称,基于监管审批进展,对Sac-TMT和博度曲妥珠销售有更乐观的预期,上调2025-27年收入预测0-5%、分别上调经PoS调整峰值预测至64亿/11亿元人民币。该行的DCF目标价上升至549港元,维持科伦博泰生物-B“买入”评级,看好临床数据驱动下ADC产品矩阵的巨大全球价值。该适应症的上市申请已于10月获批上市。2)KL166-III-06研究中,博度曲妥珠头对头战胜T-DM1,显著延长中位PFS。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990"],"gpt_icon":0},{"id":"2577657253","title":"科伦博泰生物-B盘中异动 大幅上涨3.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577657253","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577657253?lang=zh_cn&edition=fundamental","pubTime":"2025-10-22 09:30","pubTimestamp":1761096608,"startTime":"0","endTime":"0","summary":"2025年10月22日早盘09时30分,科伦博泰生物-B股票出现波动,股价快速拉升3.61%。科伦博泰生物-B股票所在的生物技术行业中,整体涨幅为0.43%。其相关个股中,同源康医药-B、维升药业-B、和铂医药-B涨幅较大,振幅较大的相关个股有康诺亚-B、科伦博泰生物-B、君实生物,振幅分别为4.56%、1.91%、1.64%。科伦博泰生物-B公司简介:四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022093008a6c6cecb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251022093008a6c6cecb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2576851949","title":"ESMO炸场!中国ADC“一哥”亮剑","url":"https://stock-news.laohu8.com/highlight/detail?id=2576851949","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576851949?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 20:18","pubTimestamp":1760962692,"startTime":"0","endTime":"0","summary":"本次ESMO大会上,TROP2 ADC芦康沙妥珠单抗有两项III期临床研究入选LBA并作口头报告,均为支持新适应症上市的关键临床数据。OptiTROP-Lung04旨在评估芦康沙妥珠单抗单药对比培美曲塞联合铂类用于经EGFR-TKI治疗失败的EGFR突变NSCLC患者的有效性和安全性。这一积极结果,使其成为全球首个针对二线EGFR突变型NSCLC人群实现PFS与OS双重获益的ADC药物,填补了该治疗领域长期存在的关键空白。胃癌是全球发病率第五、死亡率第四的恶性肿瘤,而中国更是胃癌高发国家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","06990","LU0196878994.USD","BK1161","ADC","BK4080"],"gpt_icon":0},{"id":"2576396258","title":"医药行业再传捷报!科伦博泰重磅乳腺癌创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576396258","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576396258?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 11:15","pubTimestamp":1760930156,"startTime":"0","endTime":"0","summary":"10月17日,国家药品监督管理局发布消息,四川科伦博泰生物医药股份有限公司申报的注射用博度曲妥珠单抗获批上市,用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。乳腺癌作为一种常见的恶性肿瘤,严重威胁女性健康。舒泰莱的获批上市将为相关乳腺癌患者患者带来新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020112043a6c2d5c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251020112043a6c2d5c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1574","BK1161","06978","LU0196878994.USD"],"gpt_icon":0},{"id":"1135350783","title":"科伦博泰生物-B在ESMO总统会议上展示的Sacituzumab Tirumotecan三期Optitrop-Lung04试验积极结果同时发表在NEJM","url":"https://stock-news.laohu8.com/highlight/detail?id=1135350783","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135350783?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 10:02","pubTimestamp":1760925730,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B在ESMO总统会议上展示的Sacituzumab Tirumotecan三期Optitrop-Lung04试验积极结果同时发表在NEJM","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2576888757","title":"港股异动 | 科伦博泰生物-B(06990)高开逾5% 于2025 ESMO大会上公布佳泰莱®等多项临床研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2576888757","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576888757?lang=zh_cn&edition=fundamental","pubTime":"2025-10-20 09:26","pubTimestamp":1760923585,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科伦博泰生物-B(06990)高开逾5%,截至发稿,涨5.37%,报483港元,成交额159.39万港元。消息面上,科伦博泰生物-B发布公告,本公司已在于10月17日至21日在德国柏林举行的2025年欧洲肿瘤内科学会(ESMO)大会上公布多项临床研究成果,涵盖靶向人滋养细胞表面抗塬2(TROP2)抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT)(佳泰莱®)、靶向人类表皮生长因子受体2(HER2)ADC博度曲妥珠单抗(亦称A166)(舒泰莱®)以及Claudin18.2 (CLDN18.2) ADC SKB315的相关数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":197,"code":"91000000","status":"200"}]}}